Full-Time

Senior Scientist

Regenerative Medicine

Bio-Techne

Bio-Techne

1,001-5,000 employees

Purified proteins and reagents supplier

Compensation Overview

$87.6k - $144k/yr

Minneapolis, MN, USA

In Person

Category
Medical, Clinical & Veterinary (1)
Requirements
  • Ph.D. in Biology, Biomedical Engineering, Chemical Engineering, or a related field.
  • A minimum of 2+ years of industry experience in cell and gene therapy, regenerative medicine, or biomanufacturing.
  • Translational research experience applying organoid models to disease biology, drug discovery, and/or therapeutic screening.
  • Proven expertise in process development for stem cell-based therapy research, including scaling workflows from discovery to GMP-compliant manufacturing.
  • Hands-on experience with adherent cell culture systems and advanced bioreactor platforms for large-scale cell expansion and differentiation.
  • Significant technical expertise/scientific knowledge of autologous or allogeneic cell therapies or differentiation pathways.
  • Expertise in fluorescence microscopy and standard cell characterization assays (RT-PCR, flow cytometry, ELISA, ICC) required.
  • High throughput assays or high content imaging experience strongly preferred.
  • Experience with gene editing technologies (CRISPR) and biomaterials for advanced cell culture a plus.
  • Prior demonstrated experience developing and validating/verifying product workflows under design control using a requirements-driven, risk-based approach within the biotech industry or clinical laboratory.
  • Strong background in developing and optimizing differentiation protocols for iPSCs or other pluripotent stem cells, with an emphasis on clinical and manufacturing applications.
Responsibilities
  • Identify and develop products, workflows, and key culture optimizations (i.e. expansion, differentiation, and characterization) for stem cell-based therapy and organoid research and application.
  • Develop and optimize robust and reproducible cell differentiation protocols, analytical methods, and other processes needed to convert human induced pluripotent stem cells into cellular products and therapeutics.
  • Lead core teams and collaborate with cross-functional teams to formulate cell differentiation reagents and protocols for different iPSC-derived cell types.
  • Serve as a subject matter expert in organoids, supporting new product initiatives including organoid model development, disease modeling applications, drug screening platforms, and protocol scale-up.
  • Develop cell-based, biochemical, and/or molecular assays to characterize the identity and physiology of stem cell-derived differentiated cells and organoids.
  • Plan and perform experiments, analyze data, and generate presentations to inform project progress to wider department and leadership.
  • Provide substantial, high-quality contributions to projects by working independently, communicating effectively within cross-functional team and leverage available expertise and support across the organization.
  • Contribute to corporate scientific activities/roadmaps/strategy.
  • Develop scientific content including conference presentations, publications, application notes, webinars and other Sales and Marketing efforts to support and promote Bio-Techne’s stem cell, organoids, and regenerative medicine product offerings and services.
  • Apply scientific methods and process design principles to improve development, manufacturing and quality control processes.
  • Author documentation including standard operating procedures (including Manufacturing and QC) for RUO and GMP products, design verification and validation procedures, and technical reports to support lab operation, development initiatives, and product investigations.
  • Stay up to date with the latest scientific developments and market offerings in the fields of stem cell, organoids, and regenerative medicine.
  • Provide subject matter expertise, mentorship, and leadership to other scientists and research associates across the department and the wider Bio-Techne team.
Desired Qualifications
  • High throughput assays or high content imaging experience strongly preferred.
  • Experience with gene editing technologies (e.g. CRISPR) and biomaterials for advanced cell culture a plus.

Bio-Techne makes and sells life-science tools such as purified proteins, cytokines, growth factors, antibodies, immunoassays, and reagent solutions, along with ProteinSimple analytics and cell/gene therapy workflow technologies. Researchers use these products to produce, analyze, and quantify biomolecules and to carry out assays and workflow steps in cancer, immunology, and regenerative medicine. The company differentiates itself with a broad, integrated catalog and end-to-end support—from raw proteins to analytical solutions—delivered to a global customer base. Its goal is to be a leading provider of life-science tools that speed up discovery and development in healthcare and biology.

Company Size

1,001-5,000

Company Stage

IPO

Headquarters

Minneapolis, Minnesota

Founded

1981

Simplify Jobs

Simplify's Take

What believers are saying

  • GMP proteins business grew nearly 50% YoY in Q3 2026, driven by cell therapy demand.
  • Spatial Biology segment achieved mid-teens organic growth in Q3 2026 with COMET expansions.
  • US academic market stabilized with NIH budget clarity; China posted fourth consecutive quarter growth.

What critics are saying

  • Q3 2026 revenue missed consensus by $5.7M; emerging biotech spending collapsed high single digits.
  • Exosome Diagnostics divestiture strips $20M+ annual revenue without replacement in fiscal 2026.
  • Revvity and 10x Genomics capture large pharma share with faster proteomics and spatial imaging.

What makes Bio-Techne unique

  • 80% consumables revenue provides stable, recurring revenue base versus instrument-dependent competitors.
  • COMET spatial biology platform with modular SPYRE panels reduces optimization time for researchers.
  • Large pharma customers delivered six consecutive quarters of double-digit growth through Q3 2026.

Help us improve and share your feedback! Did you find this helpful?

Your Connections

People at Bio-Techne who can refer or advise you

Benefits

Health Insurance

Dental Insurance

Vision Insurance

Life Insurance

Short-term Disability

Long-term Disability

Pet Insurance

Legal Services

401(k) Company Match

Company Equity

Professional Development Budget

Paid Vacation

Paid Sick Leave

Paid Holidays

Parental Leave

Unlimited Paid Time Off

Hybrid Work Options

Employee Stock Purchase Plan

Company News

Yahoo Finance
Mar 26th, 2026
Bio-Techne tops Q4 research tools earnings with $295.9M revenue beat

Bio-Techne reported fourth-quarter revenues of $295.9 million, flat year-on-year but exceeding analysts' expectations by 2%. The life sciences company, which manufactures specialised reagents, instruments and services for research and diagnostic testing, delivered a strong quarter with an impressive beat on organic revenue estimates. Across the research tools and consumables sector, the 10 tracked companies reported satisfactory Q4 results, with revenues beating consensus estimates by 1.2%. However, share prices have struggled, falling an average of 18.6% since the latest earnings results. The subsector faces challenges including high R&D investment requirements, pricing pressures and vulnerability to research funding cycles, though opportunities exist in emerging fields like synthetic biology and laboratory automation.

PR Newswire
Mar 25th, 2026
Bio-Techne expands COMET spatial biology suite with new SPYRE Focus Panels and Amplification Kits

Bio-Techne Corporation has expanded its COMET spatial biology portfolio with new SPYRE Focus Panels and SPYRE Amplification Kits. The additions include Stroma and Vessel panels, alongside enhanced detection capabilities using sequential and enhanced layered amplification (seqLA) technology for low-abundance targets. The modular antibody panels feature validated antibodies with ready-to-use protocols, allowing researchers to reduce optimisation time whilst maintaining flexibility to incorporate their own markers. Updated HORIZON Image Analysis Software supports the new tools, streamlining tissue analysis workflows. The enhancements strengthen Bio-Techne's integrated spatial biology ecosystem for research and preclinical therapeutic development. Bio-Techne generated over $1.2 billion in net sales in fiscal 2025 and employs approximately 3,100 people worldwide.

Bio-Techne
Mar 25th, 2026
Bio-Techne advances Spatial Biology with modular expansion of COMET(TM) Suite.

Bio-Techne advances Spatial Biology with modular expansion of COMET(TM) Suite. March 25, 2026 * New SPYRE(TM) Focus Panels (Stroma and Vessel) broaden modular panel options, enabling deeper targeted insights in spatial biology workflows. * SPYRE(TM) Amplification Kits leverage sequential and enhanced layered amplification (seqLA(TM) technology enabling improved detection of low-abundance and challenging targets. * Enhancements strengthen the fully integrated COMET spatial biology ecosystem, supporting increased consumables adoption and panel expansion. MINNEAPOLIS, March 25, 2026 /PRNewswire/ - Bio-Techne Corporation (NASDAQ: TECH), a global provider of life science tools, reagents and diagnostic products, today announced the expansion of its COMET(TM) solution portfolio with the addition of the new SPYRE(TM) Focus Panels and SPYRE(TM) Amplification Kits. Together, these strengthen the COMET technology modular, automated spatial biology workflow, delivering expanded flexibility, greater sensitivity, and enabling deeper, more focused interrogation of biologically meaningful data from initial assay design through final interpretation. To support these updates, new features of HORIZON(TM) Image Analysis Software have also been introduced, tailored for COMET hyperplex images using the new SPYRE tools, further streamlining tissue analysis. "Researchers need tools that make it easier to extract meaningful answers from complex tissue samples," said Steve Crouse, President of Bio-Techne's Diagnostics and Spatial Biology Segment. "Innovation is one of Bio-Techne's key differentiators, and SPYRE Focus Panels and SPYRE Amplification Kits reflect that strength. By incorporating these capabilities into the COMET Suite, we are giving researchers a more flexible, faster, and higher sensitivity workflow that enables researchers to achieve deeper insights with greater confidence." SPYRE(TM) Antibody Panels, including the newly introduced Stroma and Vessel Focused Panels, are modular antibody panels designed to enable flexible multiplex assay design while reducing optimization time. Panels leverage validated antibodies with ready-to-use protocols to streamline setup while maintaining flexibility to incorporate markers from a lab's own antibody library. SPYRE(TM) Amplification Kits use seqLA(TM) technology to improve the detection of low-abundance and difficult-to-detect targets. "Utilizing the pre-optimized SPYRE panel has not only increased the capacity of conventional multiplex immunofluorescence but also enabled a one-day experimental protocol," said Prof. Joanne Edwards, Professor of Translational Cancer Pathology, University of Glasgow. "The COMET workflow is straightforward and flexible, allowing us to easily integrate our own antibodies of interest. This technology provides insightful data, facilitating the simultaneous investigation of tumor and microenvironment cells within the same sample." Together, SPYRE Focus Panels and SPYRE Amplification Kits strengthen Bio-Techne's commitment to deliver a fully integrated, modular, and automated spatial biology ecosystem that accelerates research and preclinical therapeutic development. These innovations continue to empower researchers to generate richer data and deeper biological understanding from every tissue sample. ABOUT BIO-TECHNE: Bio-Techne Corporation (NASDAQ: TECH) is a global life sciences company providing innovative tools and bioactive reagents for the research and clinical diagnostic communities. Bio-Techne products assist scientific investigations into biological processes and the nature and progress of specific diseases. They aid in drug discovery efforts and provide the means for accurate clinical tests and diagnoses. With hundreds of thousands of products in its portfolio, Bio-Techne generated over $1.2 billion in net sales in fiscal 2025 and has approximately 3,100 employees worldwide. For more information, visit www.bio-techne.com or follow the Company on social media at LinkedIn, X and YouTube. MEDIA CONTACTS: David Clair, Vice President Investor Relations [email protected] SOURCE Bio-Techne Corporation Released March 25, 2026

Yahoo Finance
Mar 11th, 2026
Bio-Techne added to Madison Mid Cap Fund amid research spending concerns

Bio-Techne Corporation, a life sciences research leader, was added to Madison Mid Cap Fund's portfolio in the fourth quarter of 2025, according to the fund's investor letter. The company manufactures and sells life science reagents, instruments and services, including over 6,000 proteins, 400,000 antibody types and 2,400 diagnostic assays. Madison Mid Cap Fund cited Bio-Techne's recurring revenue model, which comprises approximately 80% of its business, and expressed optimism about the new CEO's strategy to expand the company's leadership position in protein research. The fund purchased shares at what it considers a discount due to concerns about customer research spending. Bio-Techne reported $295.9 million in revenue for the second quarter of fiscal 2026, unchanged from the previous quarter. The company currently has a market capitalisation of $8.26 billion.

Pathology In Practice
Feb 17th, 2026
Bio-Techne's Ella platform gains CE-IVD marking

Bio-Techne's Ella platform gains CE-IVD marking. * February 17, 2026 Bio-Techne has announced that the Ella benchtop immunoassay platform has received CE-IVD marking and is now available for sale in the European Union. Ella is a compact, cartridge-based immunoassay system that delivers accurate biomarker results in under 90 minutes with minimal hands-on time. By simplifying the manual steps of traditional immunoassays, Ella reduces operator variability and provides high-quality, reproducible data suitable for both translational research and clinical applications. The platform is compatible with Simple Plex assays, which remain for research use only, and are powered by R&D Systems antibodies and proteins. With more than 390 analytes across neuroscience, immunology, oncology, and cell and gene therapy, the Simple Plex portfolio enables researchers to maintain consistency and data quality while working efficiently across a wide range of applications. "Ella's CE-IVD certification marks a significant step forward in advancing precision diagnostics," said Will Geist, President of Bio-Techne's Protein Sciences Segment. "It reflects our commitment to providing innovative tools that enhance clinical decision-making and improve patient outcomes." With CE-IVD marking now in place, hospitals, clinical laboratories, or other European organisations may use Ella as a validated platform for in-house test development, clinical trials, or other translational activities. Diagnostic assay developers may also develop clinical applications on the Ella CE-IVD validated platform. The certification enhances confidence in Ella's performance and supports Bio-Techne's long-term goal to advance precision medicine by providing dependable, standardized solutions for biomarker detection.